13 Parents
| Identifier | Name | Description |
|---|---|---|
| DOID:7 | disease of anatomical entity | A disease that manifests in a defined anatomical structure. |
| DOID:4 | disease | A disease is a disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism. |
| DOID:0014667 | disease of metabolism | A disease that involves errors in metabolic processes of building or degradation of molecules. |
| DOID:77 | gastrointestinal system disease | A disease of anatomical entity that is located_in the gastrointestinal tract. |
| DOID:630 | genetic disease | A disease that has_material_basis_in genetic variations in the human genome. |
| DOID:3118 | hepatobiliary disease | A gastrointestinal system disease that is located_in the liver and/or biliary tract. |
| DOID:409 | liver disease | |
| DOID:3211 | lysosomal storage disease | An inherited metabolic disorder that involve an abnormal accumulation of substances inside the lysosome resulting from defects in lysosomal function. |
| DOID:655 | inherited metabolic disorder | A disease of metabolism that is characterized by enzyme deficiency or accumulation of enzymes or toxins which interfere with normal function due to inherited enzyme abnormality. |
| DOID:9455 | lipid storage disease | A lysosomal storage disease that involves the accumulation of harmful amounts of lipids (fats) in some of the body's cells and tissues. |
| DOID:9452 | steatotic liver disease | A lipid storage disease characterized by the accumulation of large vacuoles of triglyceride fat in at least 5% of hepatocytes. |
| DOID:0080208 | metabolic dysfunction-associated steatotic liver disease | A steatotic liver disease characterized by at least one of five specified cardiometabolic risk factors and no other discernible cause with normal to no alcohol use. The five cardiometabolic risk factors are: (1) higher than normal body mass index or waist circumference; (2) higher than normal serum glucose or glycated hemoglobin level, or type 2 diabetes; (3) higher than normal blood pressure or hypertensive treatment; (4) higher than normal plasma triglycerides or lipid lowering treatment; and (5) lower than normal plasma high-density lipoprotein cholesterol. |
| DOID:0080547 | metabolic dysfunction-associated steatohepatitis | A metabolic dysfunction-associated steatotic liver disease characterized by the presence of inflammation with hepatocyte injury such as ballooning, with or without fibrosis. |
12 Relations
| Relationship |
Parent Term . Identifier |
Child Term . Identifier |
|---|---|---|
| is_a | DOID:0080208 | DOID:0080547 |
| is_a | DOID:409 | DOID:0080547 |
| is_a | DOID:3118 | DOID:0080547 |
| is_a | DOID:77 | DOID:0080547 |
| is_a | DOID:655 | DOID:0080547 |
| is_a | DOID:9452 | DOID:0080547 |
| is_a | DOID:7 | DOID:0080547 |
| is_a | DOID:3211 | DOID:0080547 |
| is_a | DOID:0014667 | DOID:0080547 |
| is_a | DOID:630 | DOID:0080547 |
| is_a | DOID:9455 | DOID:0080547 |
| is_a | DOID:4 | DOID:0080547 |
